US Stock MarketDetailed Quotes

KURA Kura Oncology

Watchlist
  • 7.050
  • -0.090-1.26%
Close Mar 28 16:00 ET
  • 7.050
  • 0.0000.00%
Post 20:01 ET
569.32MMarket Cap-3.49P/E (TTM)

Kura Oncology Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
53.88M
53.88M
0
0
0
0
0
0
0
0
Operating revenue
--53.88M
--53.88M
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
49.02%247.08M
63.25%76.34M
40.99%59.88M
41.00%56.4M
48.91%54.45M
18.55%165.8M
33.01%46.76M
16.07%42.47M
13.22%40M
11.54%36.57M
Selling and administrative expenses
52.49%77.11M
69.17%24.07M
38.30%18.18M
41.08%16.68M
59.87%18.18M
7.47%50.57M
13.94%14.23M
13.11%13.15M
6.74%11.82M
-4.17%11.37M
-General and administrative expense
52.49%77.11M
69.17%24.07M
38.30%18.18M
41.08%16.68M
59.87%18.18M
7.47%50.57M
13.94%14.23M
13.11%13.15M
6.74%11.82M
-4.17%11.37M
Research and development costs
47.50%169.97M
60.66%52.27M
42.20%41.71M
40.97%39.73M
43.97%36.27M
24.16%115.24M
43.52%32.53M
17.44%29.33M
16.18%28.18M
20.46%25.19M
Operating profit
-16.52%-193.2M
51.98%-22.46M
-40.99%-59.88M
-41.00%-56.4M
-48.91%-54.45M
-18.55%-165.8M
-33.01%-46.76M
-16.07%-42.47M
-13.22%-40M
-11.54%-36.57M
Net non-operating interest income expense
61.16%21.23M
32.19%5.26M
41.57%5.48M
96.78%5.57M
97.32%4.93M
227.28%13.17M
94.71%3.98M
255.14%3.87M
401.60%2.83M
658.97%2.5M
Non-operating interest income
55.20%22.85M
29.50%5.66M
37.82%5.89M
85.73%5.97M
86.12%5.33M
246.07%14.72M
92.43%4.37M
292.20%4.28M
470.21%3.22M
769.60%2.86M
Non-operating interest expense
4.52%1.62M
2.28%403K
1.98%412K
4.91%406K
9.34%398K
576.42%1.55M
72.05%394K
--404K
--387K
--364K
Other net income (expense)
Income before tax
-12.67%-171.97M
59.80%-17.2M
-40.94%-54.4M
-36.75%-50.84M
-45.37%-49.53M
-12.36%-152.63M
-29.21%-42.79M
-8.73%-38.6M
-6.92%-37.17M
-4.98%-34.07M
Income tax
2.02M
0
Net income
-13.99%-173.98M
55.09%-19.22M
-40.94%-54.4M
-36.75%-50.84M
-45.37%-49.53M
-12.36%-152.63M
-29.21%-42.79M
-8.73%-38.6M
-6.92%-37.17M
-4.98%-34.07M
Net income continuous Operations
-13.99%-173.98M
55.09%-19.22M
-40.94%-54.4M
-36.75%-50.84M
-45.37%-49.53M
-12.36%-152.63M
-29.21%-42.79M
-8.73%-38.6M
-6.92%-37.17M
-4.98%-34.07M
Minority interest income
Net income attributable to the parent company
-13.99%-173.98M
55.09%-19.22M
-40.94%-54.4M
-36.75%-50.84M
-45.37%-49.53M
-12.36%-152.63M
-29.21%-42.79M
-8.73%-38.6M
-6.92%-37.17M
-4.98%-34.07M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-13.99%-173.98M
55.09%-19.22M
-40.94%-54.4M
-36.75%-50.84M
-45.37%-49.53M
-12.36%-152.63M
-29.21%-42.79M
-8.73%-38.6M
-6.92%-37.17M
-4.98%-34.07M
Basic earnings per share
2.88%-2.02
60.00%-0.22
-26.00%-0.63
-11.32%-0.59
-18.00%-0.59
-2.46%-2.08
-12.24%-0.55
5.66%-0.5
-1.92%-0.53
-2.04%-0.5
Diluted earnings per share
2.88%-2.02
60.00%-0.22
-26.00%-0.63
-11.32%-0.59
-18.00%-0.59
-2.46%-2.08
-12.24%-0.55
5.66%-0.5
-1.92%-0.53
-2.04%-0.5
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 53.88M53.88M00000000
Operating revenue --53.88M--53.88M--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 49.02%247.08M63.25%76.34M40.99%59.88M41.00%56.4M48.91%54.45M18.55%165.8M33.01%46.76M16.07%42.47M13.22%40M11.54%36.57M
Selling and administrative expenses 52.49%77.11M69.17%24.07M38.30%18.18M41.08%16.68M59.87%18.18M7.47%50.57M13.94%14.23M13.11%13.15M6.74%11.82M-4.17%11.37M
-General and administrative expense 52.49%77.11M69.17%24.07M38.30%18.18M41.08%16.68M59.87%18.18M7.47%50.57M13.94%14.23M13.11%13.15M6.74%11.82M-4.17%11.37M
Research and development costs 47.50%169.97M60.66%52.27M42.20%41.71M40.97%39.73M43.97%36.27M24.16%115.24M43.52%32.53M17.44%29.33M16.18%28.18M20.46%25.19M
Operating profit -16.52%-193.2M51.98%-22.46M-40.99%-59.88M-41.00%-56.4M-48.91%-54.45M-18.55%-165.8M-33.01%-46.76M-16.07%-42.47M-13.22%-40M-11.54%-36.57M
Net non-operating interest income expense 61.16%21.23M32.19%5.26M41.57%5.48M96.78%5.57M97.32%4.93M227.28%13.17M94.71%3.98M255.14%3.87M401.60%2.83M658.97%2.5M
Non-operating interest income 55.20%22.85M29.50%5.66M37.82%5.89M85.73%5.97M86.12%5.33M246.07%14.72M92.43%4.37M292.20%4.28M470.21%3.22M769.60%2.86M
Non-operating interest expense 4.52%1.62M2.28%403K1.98%412K4.91%406K9.34%398K576.42%1.55M72.05%394K--404K--387K--364K
Other net income (expense)
Income before tax -12.67%-171.97M59.80%-17.2M-40.94%-54.4M-36.75%-50.84M-45.37%-49.53M-12.36%-152.63M-29.21%-42.79M-8.73%-38.6M-6.92%-37.17M-4.98%-34.07M
Income tax 2.02M0
Net income -13.99%-173.98M55.09%-19.22M-40.94%-54.4M-36.75%-50.84M-45.37%-49.53M-12.36%-152.63M-29.21%-42.79M-8.73%-38.6M-6.92%-37.17M-4.98%-34.07M
Net income continuous Operations -13.99%-173.98M55.09%-19.22M-40.94%-54.4M-36.75%-50.84M-45.37%-49.53M-12.36%-152.63M-29.21%-42.79M-8.73%-38.6M-6.92%-37.17M-4.98%-34.07M
Minority interest income
Net income attributable to the parent company -13.99%-173.98M55.09%-19.22M-40.94%-54.4M-36.75%-50.84M-45.37%-49.53M-12.36%-152.63M-29.21%-42.79M-8.73%-38.6M-6.92%-37.17M-4.98%-34.07M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -13.99%-173.98M55.09%-19.22M-40.94%-54.4M-36.75%-50.84M-45.37%-49.53M-12.36%-152.63M-29.21%-42.79M-8.73%-38.6M-6.92%-37.17M-4.98%-34.07M
Basic earnings per share 2.88%-2.0260.00%-0.22-26.00%-0.63-11.32%-0.59-18.00%-0.59-2.46%-2.08-12.24%-0.555.66%-0.5-1.92%-0.53-2.04%-0.5
Diluted earnings per share 2.88%-2.0260.00%-0.22-26.00%-0.63-11.32%-0.59-18.00%-0.59-2.46%-2.08-12.24%-0.555.66%-0.5-1.92%-0.53-2.04%-0.5
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
Zhejiang Huaye Plastics Machinery
301616
+38.11%
Alnera Aluminium
301613
+20.00%
Tibet Duo Rui Pharmaceutical
301075
+19.99%
4
Shenzhen Vital New Material
301319
+19.99%
5
ChengDu Sheng Nuo Biotec
688117
+19.98%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.